Week In Review: Multitude Out-Licenses Tissue Factor ADC To Adcendo In $1 Billion Deal

Shanghai Multitude Therapeutics out-licensed global rights for its Tissue Factor ADC to Adcendo in a $1 billion agreement. The value of the agreement includes upfront and milestone payments, with potential royalties on sales also available.